Bifogade filer
INIT 2025 Q4 Final
Kurs
-3,93%
Likviditet
0,81 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2027-02-26 | 08:30 | Bokslutskommuniké 2026 |
| 2026-11-20 | 08:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-21 | 08:30 | Kvartalsrapport 2026-Q2 |
| 2026-06-01 | N/A | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2026-05-29 | N/A | Årsstämma |
| 2026-05-08 | 08:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-20 | - | Bokslutskommuniké 2025 |
| 2025-11-21 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-22 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-26 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2025-05-23 | - | Årsstämma |
| 2025-05-09 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-28 | - | Bokslutskommuniké 2024 |
| 2024-11-29 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-27 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2024-05-24 | - | Årsstämma |
| 2024-05-10 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-29 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2023-05-26 | - | Årsstämma |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-11-04 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-23 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2022-05-20 | - | Årsstämma |
| 2022-05-06 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-18 | - | Bokslutskommuniké 2021 |
| 2021-11-19 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-31 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2021-05-28 | - | Årsstämma |
| 2021-05-25 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-11 | - | Extra Bolagsstämma 2021 |
| 2021-02-19 | - | Bokslutskommuniké 2020 |
| 2020-11-20 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-25 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2020-05-22 | - | Årsstämma |
| 2020-05-22 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2019-11-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2019-05-23 | - | Årsstämma |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-11-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-28 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2018-05-25 | - | Årsstämma |
| 2018-05-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-01 | - | Extra Bolagsstämma 2017 |
| 2018-02-21 | - | Bokslutskommuniké 2017 |
| 2017-11-24 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | Kvartalsrapport 2017-Q1 |
| 2017-05-17 | - | X-dag ordinarie utdelning INIT 0.00 SEK |
| 2017-05-16 | - | Årsstämma |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Business highlights in Q4 2025
- In November the Company announced that its Clinical Trial Application (CTA) for a planned Phase IIa clinical proof-of-concept study in women with vulvodynia had been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and a local ethics committee.
- In December the Company initiated patient enrollment in its Phase IIa clinical proof-of-concept study evaluating pudafensine in women suffering from vulvodynia. Dosing of the first patients is expected to begin in January 2026, and completion of the study is projected by the end of 2026.
Business highlights after this reporting period
- The European FSD patent (EP4551221B1) was granted 18 Feb 2026.
Financial Highlights
| Fourth Quarter (2025-10-01 – 2025-12-31) |
| Net revenue were KDKK 0 (0) |
| Operating loss, EBIT was KDKK -6,966 (-2,701) |
| Earnings per share before and after dilution was DKK -0.04 (-0.02) |
| Cash: KDKK 26,245 (13,371) |
| Solidity: 90% (97%) |
| Full year 2025 (2025-01-01 – 2025-12-31) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -17,781 (-14,502) |
| Earnings per share before and after dilution was DKK –0.20 (-0.23) |
Solidity: equity divided by assets.
The Board of Directors have decided that interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/
For additional information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com
About Initiator Pharma
Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine and IP2018 – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye Sweden AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.